Highly purified extracellular vesicles from human cardiomyocytes demonstrate preferential uptake by human endothelial cells
File(s)d0nr04278a.pdf (3.49 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Extracellular vesicles (EVs) represent a promising cell-free alternative for treatment of cardiovascular diseases. Nevertheless, the lack of standardised and reproducible isolation methods capable of recovering pure, intact EVs presents a significant obstacle. Additionally, there is significant interest in investigating the interactions of EVs with different cardiac cell types. Here we established a robust technique for the production and isolation of EVs harvested from an enriched (>97% purity) population of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) with size exclusion chromatography. Utilizing an advanced fluorescence labelling strategy, we then investigated the interplay of the CM-EVs with the three major cellular components of the myocardium (fibroblasts, cardiomyocytes and endothelial cells) and identified that cardiac endothelial cells show preferential uptake of these EVs. Overall, our findings provide a great opportunity to overcome the translational hurdles associated with the isolation of intact, non-aggregated human iPSC-CM EVs at high purity. Furthermore, understanding in detail the interaction of the secreted EVs with their surrounding cells in the heart may open promising new avenues in the field of EV engineering for targeted delivery in cardiac regeneration.
Date Issued
2020-10-14
Date Acceptance
2020-09-14
Citation
Nanoscale, 2020, 12 (38), pp.19844-19854
ISSN
2040-3364
Publisher
Royal Society of Chemistry
Start Page
19844
End Page
19854
Journal / Book Title
Nanoscale
Volume
12
Issue
38
Copyright Statement
© The Royal Society of Chemistry 2020. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence (https://creativecommons.org/licenses/by/3.0/)
License URL
Sponsor
Commission of the European Communities
Biotechnology and Biological Sciences Research Council
British Heart Foundation
British Heart Foundation
British Heart Foundation
GlaxoSmithKline Services Unlimited
Grant Number
659175
BB/N503952/1
FS/16/76/32409
RM/17/1/33377
RE/13/4/30184
Mark Buswell
Subjects
02 Physical Sciences
03 Chemical Sciences
10 Technology
Nanoscience & Nanotechnology
Publication Status
Published
Date Publish Online
2020-09-24